title,datetime,impact_score,sentiment,summary,article
Gold Royalty Announces Board Change,2024-04-21T00:00:00.000Z,Low,Neutral,"Gold Royalty Corp. announces Glenn Mullan stepping down as a director of the company. The news was released on April 20, 2024.","Gold Royalty Announces Board Change Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary English French German Italian Korean Spanish Gold Royalty Corp. announces Glenn Mullan stepping down as a director of the company. The news was released on April 20, 2024. Gold Royalty Corp. annuncia le dimissioni di Glenn Mullan dalla carica di direttore della società. La notizia è stata pubblicata il 20 aprile 2024. Gold Royalty Corp. anuncia que Glenn Mullan se retira como director de la empresa. La noticia se publicó el 20 de abril de 2024. 골드 로열티 코퍼레이션에서 글렌 멀란이 회사 이사직에서 사임한다고 발표했습니다. 이 소식은 2024년 4월 20일에 발표되었습니다. Gold Royalty Corp. annonce la démission de Glenn Mullan en tant que directeur de la société. L'annonce a été faite le 20 avril 2024. Gold Royalty Corp. gibt bekannt, dass Glenn Mullan als Direktor des Unternehmens zurücktritt. Die Nachricht wurde am 20. April 2024 veröffentlicht. Positive None. Negative None. 04/20/2024 - 08:00 PM VANCOUVER, BC, April 20, 2024 /PRNewswire/ - Gold Royalty Corp. (""Gold Royalty"" or the ""Company"") (NYSE American: GROY) announced today that Glenn Mullan has stepped down as a director of the Company. About Gold Royalty Corp. Gold Royalty Corp. is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. Its mission is to invest in high-quality, sustainable, and responsible mining operations to build a diversified portfolio of precious metals royalty and streaming interests that generate superior long-term returns for our shareholders. Gold Royalty's diversified portfolio currently consists primarily of net smelter return royalties on gold properties located in the Americas. View original content:https://www.prnewswire.com/news-releases/gold-royalty-announces-board-change-302122745.html SOURCE Gold Royalty Corp. Why did Glenn Mullan step down as a director of Gold Royalty Corp.? Glenn Mullan stepped down as a director of Gold Royalty Corp. for reasons undisclosed in the press release. When was Glenn Mullan's resignation announced by Gold Royalty Corp.? Glenn Mullan's resignation from Gold Royalty Corp. was announced on April 20, 2024. What is the ticker symbol for Gold Royalty Corp.? The ticker symbol for Gold Royalty Corp. is GROY. Who is Glenn Mullan in relation to Gold Royalty Corp.? Glenn Mullan was a director of Gold Royalty Corp. who has now stepped down from his position. What type of change did Gold Royalty Corp. announce recently? Gold Royalty Corp. announced a board change with Glenn Mullan stepping down as a director of the company."
BioArctic and Eisai sign research evaluation agreement regarding BAN2802,2024-04-20T11:28:00.000Z,Neutral,Neutral,"BioArctic and Eisai have signed a research evaluation agreement for BAN2802, a potential Alzheimer's treatment combining BrainTransporter™ technology with an undisclosed drug candidate. The collaboration aims to develop the next generation disease-modifying treatment for Alzheimer's disease. Eisai will evaluate the data to potentially license BAN2802, building on their successful partnership that led to the approval of Leqembi® for early Alzheimer's disease.","BioArctic and Eisai sign research evaluation agreement regarding BAN2802 Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary English French German Italian Korean Spanish BioArctic and Eisai have signed a research evaluation agreement for BAN2802, a potential Alzheimer's treatment combining BrainTransporter™ technology with an undisclosed drug candidate. The collaboration aims to develop the next generation disease-modifying treatment for Alzheimer's disease. Eisai will evaluate the data to potentially license BAN2802, building on their successful partnership that led to the approval of Leqembi® for early Alzheimer's disease. BioArctic ed Eisai hanno firmato un accordo di valutazione della ricerca per BAN2802, un potenziale trattamento per l'Alzheimer che combina la tecnologia BrainTransporter™ con un candidato farmaco non divulgato. La collaborazione mira a sviluppare il prossimo trattamento modificante la malattia per la malattia di Alzheimer. Eisai valuterà i dati per potenzialmente licenziare BAN2802, costruendo sulla loro partnership di successo che ha portato all'approvazione di Leqembi® per la malattia di Alzheimer precoce. BioArctic y Eisai han firmado un acuerdo de evaluación de investigación para BAN2802, un posible tratamiento para el Alzheimer que combina la tecnología BrainTransporter™ con un candidato a medicamento no revelado. La colaboración tiene como objetivo desarrollar el próximo tratamiento modificante de la enfermedad para la enfermedad de Alzheimer. Eisai evaluará los datos para potencialmente licenciar BAN2802, basándose en su asociación exitosa que llevó a la aprobación de Leqembi® para la enfermedad de Alzheimer en sus etapas iniciales. BioArctic과 Eisai는 미공개 약물 후보와 BrainTransporter™ 기술을 결합한 잠재적 알츠하이머 치료제 BAN2802에 대한 연구 평가 계약을 체결하였습니다. 이 협력은 알츠하이머병을 위한 차세대 질병 수정 치료제 개발을 목표로 합니다. Eisai는 BAN2802의 라이센스를 잠재적으로 평가하기 위해 데이터를 검토할 것이며, 이는 초기 알츠하이머병에 대한 Leqembi®의 승인으로 이어진 성공적인 파트너십을 바탕으로 합니다. BioArctic et Eisai ont signé un accord d'évaluation de recherche pour BAN2802, un traitement potentiel de la maladie d'Alzheimer associant la technologie BrainTransporter™ à un candidat médicamenteux non divulgué. La collaboration vise à développer le traitement modificateur de maladie de nouvelle génération pour la maladie d'Alzheimer. Eisai évaluera les données pour potentiellement licencier BAN2802, s'appuyant sur leur partenariat réussi qui a conduit à l'approbation de Leqembi® pour la maladie d'Alzheimer précoce. BioArctic und Eisai haben eine Forschungsüberprüfungsvereinbarung für BAN2802 unterzeichnet, eine potenzielle Alzheimer-Behandlung, die BrainTransporter™-Technologie mit einem nicht offengelegten Arzneimittelkandidaten kombiniert. Die Zusammenarbeit zielt darauf ab, die nächste Generation der krankheitsmodifizierenden Behandlung für Alzheimer zu entwickeln. Eisai wird die Daten bewerten, um möglicherweise BAN2802 zu lizenzieren, aufbauend auf ihrer erfolgreichen Partnerschaft, die zur Zulassung von Leqembi® für frühe Alzheimer-Krankheit geführt hat. Positive None. Negative None. 04/20/2024 - 07:28 AM STOCKHOLM, April 20, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer's disease. BioArctic and Eisai have a long-standing collaboration dating back to 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. This collaboration has led to Leqembi® (lecanemab) – the world's first approved drug[1] shown to slow the progression of early Alzheimer's disease. The new collaboration will build on the companies' joint knowledge in the field of Alzheimer's disease. Costs for the research evaluation program will be shared and the program will evaluate what could be the next generation disease modifying treatment for Alzheimer's disease. ""I am very happy that our Brain Transporter technology has continued to progress so well and that we have now entered into this first agreement utilizing this platform. I believe that this technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders,"" said Gunilla Osswald, CEO at BioArctic. ""Eisai has been a valuable partner to BioArctic during the past two decades, and we are very pleased to extend and deepen our relationship with this new research evaluation agreement on BAN2802. Together, we have been able to deliver lecanemab, the first fully approved disease modifying treatment in Alzheimer's disease in the US, Japan and China, and we look forward to continuing our fruitful collaboration and lead the development of the next generation of drugs to help patients with this devastating disease."" BioArctic's proprietary BrainTransporter technology is a technology that can actively transport biologics across the blood brain barrier into the brain. The technology has the potential to create faster and stronger efficacy of treatments targeted to the brain, while reducing the burden of treatment for both patients and society. The BrainTransporter technology manifests BioArctic's commitment to sustainability by aiming for continuous improvement of clinical and commercial benefit. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on April 20, 2024, at 09.40 a.m. CET. For further information, please contact: Oskar Bosson, VP Communications and IRE-mail: oskar.bosson@bioarctic.sePhone: +46 70 410 71 80 About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody LEQEMBI back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se. [1] Approved in the US, Japan and China. This information was brought to you by Cision http://news.cision.com https://news.cision.com/bioarctic/r/bioarctic-and-eisai-sign-research-evaluation-agreement-regarding-ban2802,c3964796 The following files are available for download: https://mb.cision.com/Main/9978/3964796/2746802.pdf BioArctic and Eisai sign research evaluation agreement regarding BAN2802 View original content:https://www.prnewswire.com/news-releases/bioarctic-and-eisai-sign-research-evaluation-agreement-regarding-ban2802-302122670.html SOURCE BioArctic What is the research evaluation agreement between BioArctic and Eisai regarding? The research evaluation agreement is for BAN2802, a potential new treatment combining BioArctic's BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. What is the goal of the collaboration between BioArctic and Eisai? The collaboration aims to develop the next generation disease-modifying treatment for Alzheimer's disease by leveraging their joint knowledge and expertise in the field. What previous successful collaboration is mentioned in the press release? The collaboration between BioArctic and Eisai led to the approval of Leqembi® (lecanemab), the world's first approved drug shown to slow the progression of early Alzheimer's disease. What technology does BioArctic utilize in their research? BioArctic utilizes the BrainTransporter™ technology, which actively transports biologics across the blood brain barrier into the brain, potentially enhancing treatment efficacy. How does BioArctic demonstrate its commitment to sustainability? BioArctic demonstrates its commitment to sustainability by aiming for continuous improvement of clinical and commercial benefit through technologies like BrainTransporter™."
"Chow Tai Fook Jewellery Group Shines on Global Stage with Paris 100 Sponsorship, Promoting Chinese Craftsmanship to Celebrate 95 Years of Heritage",2024-04-20T10:30:00.000Z,No impact,Very Positive,"Chow Tai Fook Jewellery Group sponsors the prestigious Paris 100 event, celebrating Chinese-French cultural ties and promoting Chinese craftsmanship globally. The event marks the 60th anniversary of China-France cultural exchange and the countdown to the 2024 Paris Olympics. The sponsorship showcases the Group's commitment to cultural exchange and art appreciation, reinforcing its vision as the leading global jewellery brand.","Chow Tai Fook Jewellery Group Shines on Global Stage with Paris 100 Sponsorship, Promoting Chinese Craftsmanship to Celebrate 95 Years of Heritage Rhea-AI Impact (No impact) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary English French German Italian Korean Spanish Chow Tai Fook Jewellery Group sponsors the prestigious Paris 100 event, celebrating Chinese-French cultural ties and promoting Chinese craftsmanship globally. The event marks the 60th anniversary of China-France cultural exchange and the countdown to the 2024 Paris Olympics. The sponsorship showcases the Group's commitment to cultural exchange and art appreciation, reinforcing its vision as the leading global jewellery brand. Il Gruppo Chow Tai Fook Jewellery sponsorizza il prestigioso evento Paris 100, celebrando i legami culturali cino-francesi e promuovendo l'artigianato cinese a livello globale. L'evento segna il 60° anniversario dello scambio culturale tra Cina e Francia e il conto alla rovescia per le Olimpiadi di Parigi 2024. La sponsorizzazione dimostra l'impegno del Gruppo verso lo scambio culturale e l'apprezzamento artistico, rafforzando la sua visione come leader mondiale nel settore della gioielleria. El Grupo Chow Tai Fook Jewellery patrocina el prestigioso evento Paris 100, celebrando los lazos culturales chino-franceses y promoviendo la artesanía china a nivel mundial. El evento marca el 60 aniversario del intercambio cultural entre China y Francia y la cuenta regresiva para los Juegos Olímpicos de París 2024. El patrocinio muestra el compromiso del Grupo con el intercambio cultural y la valoración del arte, reforzando su visión como la marca líder global de joyería. Chow Tai Fook 주얼리 그룹이 프랑스 파리 100 행사를 후원하며 중국과 프랑스의 문화적 유대를 기념하고 전 세계적으로 중국 수공예를 홍보합니다. 이 행사는 중국과 프랑스 간의 문화 교류 60주년과 2024 파리 올림픽 카운트다운을 표시합니다. 이 후원은 문화 교환과 예술 감상에 대한 그룹의 헌신을 보여주며, 글로벌 보석 브랜드로서의 선도적 비전을 강화합니다. Le Groupe Chow Tai Fook Jewellery parraine l'événement prestigieux Paris 100, célébrant les liens culturels sino-français et promouvant l'artisanat chinois à l'échelle mondiale. L'événement marque le 60e anniversaire de l'échange culturel entre la Chine et la France et le compte à rebours pour les Jeux Olympiques de Paris 2024. Le parrainage démontre l'engagement du groupe en faveur de l'échange culturel et de l'appréciation artistique, renforçant sa vision en tant que marque de bijouterie leader mondiale. Die Chow Tai Fook Jewellery Group sponsert das renommierte Paris 100 Event, das die chinesisch-französischen Kulturverbindungen feiert und chinesisches Handwerk weltweit fördert. Die Veranstaltung markiert den 60. Jahrestag des kulturellen Austausches zwischen China und Frankreich und den Countdown zu den Olympischen Spielen 2024 in Paris. Das Sponsoring unterstreicht das Engagement der Gruppe für kulturellen Austausch und Kunstwertschätzung und verstärkt ihre Vision als führende globale Schmuckmarke. Positive Chow Tai Fook Jewellery Group sponsors the Paris 100 event to celebrate Chinese-French cultural harmony and shared values. The sponsorship aligns with the Group's 95th-anniversary celebration and brand transformation journey. The event marks a milestone in promoting Chinese culture and exceptional craftsmanship worldwide. Chow Tai Fook Jewellery Group donates proceeds from a special auction to support local badminton clubs and aspiring athletes. The Group launches the 'Paris 100' Collection, commemorating China-France relations and the upcoming Paris 2024 Summer Olympics. The collection highlights the shuttlecock as a central theme, symbolizing the spirit of international connections through badminton. Chow Tai Fook Jewellery Group combines exquisite craftsmanship with historical heritage to create the 'Paris 100' Collection. The Group's participation in the event underscores its dedication to upholding Chinese heritage and inspiring global audiences. Chow Tai Fook Jewellery Group's vision is to be the leading global jewellery brand, trusted by every generation. The Group's commitment to innovation, craftsmanship, and excellence drives its success and customer engagement. Negative None. 04/20/2024 - 06:30 AM HONG KONG, CHINA / ACCESSWIRE / April 20, 2024 / Chow Tai Fook Jewellery Group Limited (""Chow Tai Fook Jewellery Group"", the ""Group"" or the ""Company""; SEHK stock code: 1929), the leading Chinese jeweller built on nearly a century of trust and innovation, is proud to announce its sponsorship of the prestigious Paris 100 ""China-France badminton friendly exhibition match"" (""Paris 100""). This sponsorship coincides with the 60th anniversary of the China-France Year of Culture and Tourism, as well as the exhilarating countdown of 100 days to the 2024 Paris Olympic Games. As part of the Group's series of initiatives to celebrate its 95th anniversary and brand transformation journey, the sponsorship of Paris 100 marks the first milestone in its journey, exemplifying Chow Tai Fook Jewellery's unwavering commitment to promoting Chinese culture and exceptional craftsmanship to a global audience.Honouring Chinese Culture and Craftsmanship on a Global ScaleThe Paris 100, held on 17 April in Paris, celebrates the cultural harmony and shared appreciation for sports and the arts between China and France.Initiated by the legendary Chinese badminton Grand Slam and Olympic Gold Medallist, Lin Dan, along with other badminton legends, this exceptional event unites the two nations to celebrate their shared values and historical achievements. Ambassador Lu Shaye, Embassy of the People's Republic of China in the Republic of France, and Ms. Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group, attended and demonstrated their support for this significant cultural event.Uniting rich cultural heritage and a shared appreciation for art and aesthetics, the China-France relationship has given rise to iconic landmarks like the Eiffel Tower, the Louvre Museum, the Great Wall, and the Imperial Palace. Building upon this remarkable historical milestone, Chow Tai Fook Jewellery embraces its mission to promote cultural exchange and mutual art appreciation.""As Chow Tai Fook Jewellery Group commemorates our 95th anniversary and the start of our transformative brand journey, April holds special significance for us. We are honoured to be a part of the prestigious Paris 100 event, which aligns seamlessly with our focus on excellence. We are delighted to bring Chinese culture at the forefront of the global stage, while also celebrating the rich cultural ties between China and France, two nations connected by the beauty and ingenuity of heritage in excellent craftsmanship."" said Ms. Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group.This momentous occasion marks a vision that sets the course for the Group's future: ""To be the leading global jewellery brand that is a trusted lifetime partner for every generation"".With this new vision, the Group is committed to upholding the highest standards of Chinese jewellery craftsmanship, while also passing on the beauty of Chinese art and culture to international audiences. Chow Tai Fook Jewellery Group's Donations in Empowering and Strengthening CommunitiesAs a testament to its commitment to support nurturing talent in sports, Chow Tai Fook Jewellery Group has specially created a 24K Pure Gold Shuttlecock Decoration for auction at this special occasion. The unique shuttlecock decoration showcases the artisan's creativity through its vivid electroformed design. When tilted at a 45-degree angle, it radiates a captivating sparkle. The decoration is elegantly showcased in a red gift box with a gold clasp bearing the auspicious Chinese character ""福"" symbolising ""good fortune"". As the clasp is turned upside down to unveil the treasure within, it beautifully represents the arrival of abundant blessings, accompanied by a subtle shimmer of gold.The auction of the shuttlecock decoration generated RMB 120,000 in funds. The organiser will donate the proceeds to the local badminton clubs under Lin Dan, Taufik Hidayat, Peter Gade and Lee Chong Wei, to promote badminton while supporting aspiring athletes and making a meaningful and positive impact in the lives of the community at large.Chow Tai Fook Jewellery Group's participation in Paris 100 marks a milestone in the Group's legacy of trust, innovation, and cultural preservation, reaffirming its position as a leading Chinese jeweller dedicated to upholding Chinese heritage while captivating and inspiring audiences worldwide.Immaculate Craftsmanship Passed Down Generations - Launch of ""Paris 100"" CollectionChow Tai Fook Jewellery proudly presents the ""Paris 100"" Collection, a tribute marking the 60th anniversary of China-France relations and the upcoming Paris 2024 Summer Olympics. This meticulously crafted collection captures the spirit of international connections fostered through the sport of badminton.Crafted through exquisite craftsmanship inherited from years of history and heritage, the ""Paris 100"" Collection highlights the shared values of the two nations, focusing on the shuttlecock as a central theme. Its design artfully combines elements of the French national flag, the Eiffel Tower, and the shuttlecock itself, symbolising France's commitment to embracing its rich history, while showcasing the spirt of inclusivity and creativity in sports. Included in the collection are a 18K White Gold Diamond Necklace and a 24K Pure Gold Necklace, immaculately depicting the unique aspects and three dimensions of the shuttlecock by utilising the gold spinel technique.Photography/ captions: Photo of Ambassador Lu Shaye, Embassy of the People's Republic of China in the Republic of France (third from left), taken at the event with Ms. Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group (third from right), Mr Lin Dan (first from right), Mr Taufik Hidayat (second from right), Mr Lee Chong Wei (first from left) and Mr Peter Gade (second from left) The 24K Pure Gold Shuttlecock Decoration for auction at the ""Paris 100"" event Chow Tai Fook Jewellery's ""Paris 100"" Collection###Chow Tai Fook Jewellery Group Limited Chow Tai Fook Jewellery Group Limited (the ""Group""; SEHK stock code: 1929) was listed on the Main Board of The Stock Exchange of Hong Kong in December 2011. The Group celebrates its 95th anniversary this year, guided by a vision: ""To be the leading global jewellery brand that is a trusted lifetime partner for every generation"".Founded in 1929, the Group's iconic brand ""CHOW TAI FOOK"" has become an emblem of tradition, celebrated for its bold designs and an unwavering attention to detail. Building upon a rich heritage and a foundation of trust, the Group is not only widely recognised for honouring traditions but also for fostering deep, meaningful connections with a diverse customer base through its products. The Group's long-standing commitment to innovation and craftsmanship has been integral to its success over time and has become synonymous with excellence, value and authenticity.As a leading Chinese jeweller, the Group believes in blending contemporary cutting-edge designs with traditional techniques to create jewellery that can be passed down from generation to generation. Every collection is thoughtfully conceived and crafted to reflect the stories of our customers, celebrating the special moments in their lives. Committed to growing alongside our customers, the Group embraces a spirit that aspires to inspire and captivate generations to come, weaving the story of CHOW TAI FOOK into the fabric of their lives.Offering a wide variety of products, services and channels, the Group's brand portfolio comprises the CHOW TAI FOOK flagship brand with curated retail experiences, and other individual brands including HEARTS ON FIRE, ENZO, SOINLOVE and MONOLOGUE.The Group is committed to delivering sustainable long-term value creation for its stakeholders by enhancing the quality of earnings and driving higher value growth. With an extensive retail network of nearly 8,000 stores across China as well as multiple locations globally, and a growing e-commerce business, the Group is implementing targeted online-to-offline (""O2O"") strategies to strengthen its competitiveness in today's omni-channel retail environment.Media Enquiries:Chow Tai Fook Jewellery Group Limited Haide NgSenior Manager, Investor Relations and Corporate CommunicationsTel: (852) 3115 4402Email: haideng@chowtaifook.comAcky ChanSenior Manager, Investor Relations and Corporate CommunicationsTel: (852) 3115 4403Email: ackychan@chowtaifook.comFile: Chow Tai Fook Jewellery Group Shines on Global Stage with Paris 100 Sponsorship, Promoting Chinese Craftsmanship to Celebrate 95 Years of HeritageSOURCE: Chow Tai Fook Jewellery Group LimitedView the original press release on accesswire.com What event did Chow Tai Fook Jewellery Group sponsor recently? Chow Tai Fook Jewellery Group sponsored the prestigious Paris 100 event. What does the 'Paris 100' event celebrate? The 'Paris 100' event celebrates the cultural harmony between China and France. What milestone does the sponsorship of Paris 100 mark for Chow Tai Fook Jewellery Group? The sponsorship marks a milestone in the Group's journey to promote Chinese culture and craftsmanship globally. How did Chow Tai Fook Jewellery Group support local badminton clubs? The Group donated proceeds from an auction to support local badminton clubs and aspiring athletes. What does the 'Paris 100' Collection represent? The collection represents the spirit of international connections through badminton. What is Chow Tai Fook Jewellery Group's vision for the future? The Group aims to be the leading global jewellery brand, trusted by every generation."
